Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FSD201 in Idiopathic Mast Cell Activation Syndrome with Chronic Pain
NCT05652907Phase 2Terminated
- Sponsor
- Quantum BioPharma Ltd.
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Mast Cell Activation Syndrome (MCAS) and chronic pain comparing FSD201 with Placebo (2 arms). Primary endpoint: Average Daily Pain Intensity at 28 days. Started Jan 2023; status: terminated.
02
Drugs
palmitoylethanolamide
03
Conditions
Mast Cell Activation Syndrome (MCAS)chronic pain
Beyond the preview
Go deeper on NCT05652907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05652907.